TQB-2102

N/A

Report date: 2026/05/15 20:01:45

Base Information

Drug NameTQB-2102
Drug Alias NameTQB-2102TQB2102
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > Cleavable peptide linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody +[4] 
Mechanisms of ActionAnti-HER2DNA topoisomerase I inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2DNA topoisomerase I
Therapy Area/IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsSolid tumours +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical GroupJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsSolid tumours +[11] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A